We’re proud to share that FAST’s Chief Operating Officer, Ryan Fischer, has been selected as a 2026 Community Congress Patient Advocacy Group Co-Chair with the EveryLife Foundation for Rare Diseases.
Ryan will co-chair the Regulatory Working Group, where the focus is improving the regulatory infrastructure and advancing regulatory science for rare disease products. In plain terms: helping make sure the rules, evidence, and pathways actually work for patients, not around them.
Ryan brings more than two decades of rare disease advocacy leadership and deep experience in patient-focused drug development. He has helped co-author legislation, led several patient preference research studies, and is known for building pre-competitive collaborations that turn patient insight into evidence decision-makers can actually use.
We’re proud of what this represents for Angelman syndrome advocacy. We work alongside the Angelman Syndrome Foundation through Hope in Action to push policy priorities for our families, and this is an important step in that work.